Navigation Links
Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
Date:9/21/2011

nts or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review and approval is uncertain; the risk that data and other information related to Arena's research and development programs may not meet safety or efficacy requirements or otherwise be sufficient for regulatory approval; Arena's response to the CRL for the lorcaserin NDA or submission of a Marketing Authorization Application for regulatory approval of lorcaserin may not be submitted when anticipated, if at all; the FDA may request other information prior to or after Arena submits such response or approval of the lorcaserin NDA; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Arena Pharmaceuticals, Inc.Robert E. Hoffman, Vice President, Finance and C
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
2. Arena Pharmaceuticals Announces Second Quarter 2011 Financial Results
3. Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study
4. Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses
5. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
6. Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
7. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
8. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
9. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
10. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
11. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... 20, 2015 Research and ... the "Global Pressure Relief Devices Market 2015-2019" ... Relief Devices market to grow at a CAGR of ... Pressure Relief Devices Market 2015-2019, has been prepared based ... experts. The report covers the Americas, and the APAC ...
(Date:7/27/2015)... 27, 2015  Attorney Advertising-- Bronstein, Gewirtz & Grossman, ... purchasers of the securities of AMAG Pharmaceuticals Inc. ... investors are advised to contact Peretz Bronstein ... Kimelman at info@bgandg.com or 212-697-6484. ... certain of its officers and/or directors have violated ...
(Date:7/27/2015)... , July 20, 2015 Research and Markets ... "Medical Device Regulation in Asia/Pacific Markets Seminar" ... the European Medical Device market is well established, the ... China , together with other countries ... the process of implementing, their own medical device regulations. ...
Breaking Medicine Technology:Global Pressure Relief Devices Market 2015-2019 with ArjoHuntleigh, Hill-Rom, Paramount Bed Holdings & Stryker Dominating 2SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals Inc. 2Medical Device Regulation in Asia/Pacific Markets Seminar: London, UK - 21st, 22nd of September 2015 2
... Myocor, Inc. announced that,the U.S. Food and ... Valvular and Ventricular Improvement Via iCoapsys Delivery ... evaluate the,safety and feasibility of the percutaneously ... valve insufficiency caused by left,ventricular dysfunction and ...
... Senesco,Technologies, Inc. ("Senesco" or the "Company") (Amex: ... lab studies at Mayo Clinic focused,on multiple myeloma. ... Factor 5A gene technology to up-regulate apoptosis of ... for,encapsulation of Factor 5A to enhance the time ...
Cached Medicine Technology:Myocor Receives Approval for Percutaneous Trial 2Senesco Technologies Initiates Preclinical Studies for Cancer Target 2
(Date:7/27/2015)... NJ (PRWEB) , ... July 27, 2015 , ... ... entitled "Applying Data To Reduce Hospital Readmissions." , The Centers for Medicare and ... facility-level data used as part of their penalty calculation. Known as the QualityNet ...
(Date:7/27/2015)... ... July 27, 2015 , ... At Champagne Smiles, they know that ... loss can incur a lot of stress, pain, discomfort and embarrassment, which is why ... All-On-4™ treatment reaps the benefits of implants with the cost savings of dentures for ...
(Date:7/27/2015)... ... , ... According to an article published by the Times Free Press ... stemming from intravenous drug use. Intravenous drug use causes more overdoses and is responsible ... including Hepatitis B and C and HIV. Drug treatment facilities in Tennessee have witnessed ...
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... ... of fullerenes in medical and diagnostics applications is rapidly increasing and is driven ... and cancer treatment, they are increasingly being evaluated for use in bio implants. ...
(Date:7/27/2015)... ... ... Sher Fertility Institute, a national network of fertility clinics known ... their clinical team in Las Vegas. , Dr. Mark Severino joins ... Endocrinology teams in the region. , Combined Drs. Sher and Severino have more than ...
Breaking Medicine News(10 mins):Health News:BESLER Consulting Publishes E-book Focused on Reducing Hospital Readmissions 2Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 2Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 3Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 4Health News:Tennessee Sees an Increase in Hepatitis C Infections from Intravenous Heroin Use 2Health News:Tennessee Sees an Increase in Hepatitis C Infections from Intravenous Heroin Use 3Health News:Fullerene Market to Grow at 13% CAGR to 2019 Says a New Research Report at Sandlerresearch.org 2Health News:Fullerene Market to Grow at 13% CAGR to 2019 Says a New Research Report at Sandlerresearch.org 3Health News:Dr. Mark Severino Joins Dr. Geoffrey Sher at Sher Fertility Las Vegas- Sher Fertility is National Network of Fertility Clinics Known for Exceptional Patient Care 2Health News:Dr. Mark Severino Joins Dr. Geoffrey Sher at Sher Fertility Las Vegas- Sher Fertility is National Network of Fertility Clinics Known for Exceptional Patient Care 3
... the risk of developing breast cancer, says a new ... between handedness// and incidence of breast cancer in over ... 1941, reports science portal EurekAlert. ,They recorded ... economic status, smoking habits, family history of breast cancer, ...
... Wake Forest University Baptist Medical Center have begun a ... synthetic steroids to prevent premature babies//., ,Premature infants ... fully developed. Currently the best treatments are to give ... for as long as possible. ,Sheep will ...
... designed a plastic device which helps in prevention of ... patients//. The scarring in these cancer patients hinders the ... to reduce the risk of scarring in women undergoing ... ,Joan Thomas, is Macmillan Nurse specialist who has ...
... chemicals has been known to be associated with health ... But it is known not until recently that rheumatoid ... to mineraloil., ,The exact causative factor rheumatiod factor ... and environmental fcators have been help responsible to a ...
... might help lower the negative impact on a person's blood ... that job strain had a significant impact, both clinically and ... low marital cohesion, or a lack of support from a ... of blood pressure over one year. High marital cohesion in ...
... to lose the excess weight that one has to carry like ... best way is that adopted earlier that is the basic principle ... Obesity is a big problem these days., ,Calorie counting ... towards weight control., ,With so many dietary plans jostling for ...
Cached Medicine News:
Full plate covers seal all 24 MicroAmp tubes...
Omniseal TD mat. Reusable rubber mat for sealing PCR plates. 5 pk....
Inquire...
... A soft, heat-resistant, aluminum foil film ... AlumaSeal II minimizes evaportaion and vapor ... need for heat-sealing devices or mats. ... sovents and reagents. Compared to other ...
Medicine Products: